ANTI-S100A8/A9 FOR INHIBITING IMMUNOSUPPRESSIVE ACTIVITY OF MDSCS CELLS

A solid tumor in a subject is treated with a composition comprising a carrier and one of an anti-S100A8, an anti-S100A9, or a combination thereof. The composition diminishes the numbers of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), reduces the activity of MDSCs, and increases th...

Full description

Saved in:
Bibliographic Details
Main Authors LAOUEDJ, Malika, TESSIER, Philippe, DEFRENE, Joan, BARABE, Frédéric
Format Patent
LanguageEnglish
French
Published 17.01.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A solid tumor in a subject is treated with a composition comprising a carrier and one of an anti-S100A8, an anti-S100A9, or a combination thereof. The composition diminishes the numbers of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), reduces the activity of MDSCs, and increases the numbers of CD8 cells. The composition furthermore increases the differentiation of MDSCs into mature myeloid cells in the subject. Selon l'invention, une tumeur solide chez un sujet est traitée par une composition comprenant un excipient et l'un parmi un anti-S100A8, un anti-S100A9 ou une combinaison de ceux-ci. La composition réduit le nombre de cellules suppressives dérivées de cellules myéloïdes polymorphonucléaires (PMN-MDSC), réduit l'activité des MDSC, et augmente les nombres de cellules CD8. La composition augmente en outre la différenciation des MDSC en cellules myéloïdes matures chez le sujet.
Bibliography:Application Number: WO2018CA50747